Literature DB >> 7891485

Renal function during antihypertensive treatment.

S Madhavan1, D Stockwell, H Cohen, M H Alderman.   

Abstract

To determine the association of renal function and the course of blood pressure in antihypertensive therapy, we studied the changes in serum creatinine as a measure of renal function and in-treatment blood pressure in black and white hypertensive patients. We measured serum creatinine in 2125 mild and moderately hypertensive men during treatment over an average of 5 years. Both unadjusted mean initial and final serum creatinine of 758 blacks (113 and 117 mumol/L respectively) were significantly higher than those of 1367 whites (108 and 107 mumol/L), with a small increase of 4 mumol/L (p < 0.01) for blacks and a fall of 0.9 mumol/L (p > 0.05) for whites. Less than 2% of all patients attained or remained at a final serum creatinine of 177 mumol/L or more. Of this small group (3% blacks, 1.4% whites), 31% had proteinuria at entry. After stratification by in-treatment diastolic blood pressure (< 95 and > or = 95 mm Hg) in each race, mean slopes of reciprocal serum creatinine were estimated, adjusting for age at entry, initial serum creatinine, diastolic pressure, and body-mass index by analysis of covariance. The two adjusted mean slopes did not differ significantly within each race. Multiple regression analysis confirmed that in-treatment diastolic pressure was not independently associated with final serum creatinine. The change in renal function was most likely a reflection of regression towards the mean, and does not support the view that antihypertensive treatment is an important determinant of renal function in mild-to-moderate hypertensive patients. Patients with substantial renal insufficiency may have pre-existing intrinsic renal disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7891485     DOI: 10.1016/s0140-6736(95)90638-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  7 in total

1.  Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data.

Authors:  L S Vest; F M Koraishy; Z Zhang; N N Lam; M A Schnitzler; V R Dharnidharka; D Axelrod; A S Naik; T A Alhamad; B L Kasiske; G P Hess; K L Lentine
Journal:  Clin Transplant       Date:  2018-06-29       Impact factor: 2.863

Review 2.  ACE inhibitors and the kidney. A risk-benefit assessment.

Authors:  G Navis; H J Faber; D de Zeeuw; P E de Jong
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

3.  Importance of blood pressure reduction for prevention of progression of renal disease.

Authors:  S C Textor; V J Canzanello
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

Review 4.  The kidney as a target of hypertension.

Authors:  S Ljungman
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

Review 5.  Renal protection by antihypertensive therapy.

Authors:  Luis M Ruilope; Julian Segura
Journal:  Curr Hypertens Rep       Date:  2002-08       Impact factor: 5.369

Review 6.  The burden of hypertension and kidney disease in Northeast India: the Institute for Indian Mother and Child noncommunicable diseases project.

Authors:  Maurizio Gallieni; Angela Aiello; Benedetta Tucci; Valeria Sala; Sujit K Brahmochary Mandal; Anna Doneda; Simonetta Genovesi
Journal:  ScientificWorldJournal       Date:  2014-01-27

7.  How relevant and frequent is the presence of mild renal insufficiency in essential hypertension?

Authors:  Julían Segura; Carlos Campo; Luis M Ruilope
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Sep-Oct       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.